001540.KQ Ahn-Gook Pharmaceutical Co. Ltd
- Market cap
- KRW 107B
- P/E
- 5.0x
- P/B
- 0.60x
- ROE
- 23.4%
- Dividend yield
- 4.66%
- Fundamental score
- 4.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 001540.KQ undervalued?
Graham number001540.KQ trades 63.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ahn-Gook Pharmaceutical Co. Ltd fundamental analysis
18 of 22 checks passedROE 2/2
High return on equity (23.4%), above 20%.
ROA 1/1
Return on assets (12.6%) is above the industry median (3.4%).
Profit Consistency 2/2
Profitable for 5 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-55.6%) is below the industry median (6.6%).
Revenue Growth 2/2
Revenue grew 14.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (28.0%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 22.0x against interest expense, well covered.
PE vs Market 1/1
PE (5.0x) is below the market median (11.3x).
PE vs Industry 1/1
PE (5.0x) is below the industry median (19.4x).
PBV 1/1
Price to book (0.6x) is below the industry median (0.8x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 3.0, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 2/2
Dividend yield (4.7%) is in the top 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 66.8%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Ahn-Gook Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.
Full company profileAhn-Gook Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ahn-Gook Pharmaceutical Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 174B | 184B | 186B | 156B | 143B | 164B | 205B | 234B | 271B | 307B | 382B |
| Gross Profit | 70.4B | 92.2B | 97.8B | 78.0B | 84.9B | 101B | 126B | 141B | 168B | 200B | 256B |
| Operating Income | 2.55B | 10.2B | 15.0B | 862M | -61.2M | -1.08B | 9.17B | 5.00B | 6.48B | 9.82B | 49.3B |
| EBITDA | - | - | - | - | - | - | 12.5B | 9.43B | 30.9B | 19.2B | 67.0B |
| Net Income | 1.72B | 8.16B | 13.2B | 2.54B | -1.32B | 3.94B | 6.88B | 1.29B | 16.8B | 7.48B | 41.7B |
| EPS | 150 | 712 | 1,154 | 221 | -115 | 345 | 605 | 114 | 1,482 | 658 | 3,672 |
| Balance Sheet | |||||||||||
| Total Assets | 196B | 208B | 213B | 218B | 202B | 212B | 224B | 239B | 303B | 311B | 331B |
| Total Liabilities | 65.4B | 71.1B | 66.2B | 69.7B | 57.6B | 66.5B | 69.1B | 86.9B | 137B | 145B | 151B |
| Shareholders' Equity | 131B | 137B | 147B | 148B | 144B | 145B | 155B | 152B | 166B | 165B | 179B |
| Cash & Short-term Investments | 42.5B | 48.0B | 54.8B | 79.3B | 48.6B | 46.2B | 36.1B | 35.4B | 29.7B | 38.9B | 56.1B |
| Total Debt | 11.8B | 10.7B | 10.6B | 18.5B | 20.3B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.6B | 17.5B | -1.20B | 22.1B | 11.2B | 1.47B | 1.79B | -1.33B | 4.91B | 45.7B | 45.4B |
| Capital Expenditure | 4.38B | 4.79B | 2.91B | 3.74B | 24.1B | 4.04B | 2.93B | 5.47B | 75.9B | 8.67B | 15.5B |
| Free Cash Flow | - | - | - | 14.3B | -13.3B | -3.69B | -1.99B | -7.56B | -71.4B | 37.0B | 29.9B |
| Ratios | |||||||||||
| ROE | 1.3% | 6.0% | 9.0% | 1.7% | -0.9% | 2.7% | 4.4% | 0.8% | 10.2% | 4.5% | 23.4% |
| ROA | 0.9% | 3.9% | 6.2% | 1.2% | -0.7% | 1.9% | 3.1% | 0.5% | 5.6% | 2.4% | 12.6% |
| Net Profit Margin | 1.0% | 4.4% | 7.1% | 1.6% | -0.9% | 2.4% | 3.3% | 0.6% | 6.2% | 2.4% | 10.9% |
| Debt to Equity | 0.09x | 0.08x | 0.07x | 0.13x | 0.14x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ahn-Gook Pharmaceutical Co. Ltd dividends
- Dividend yield
- 4.66%
- Forward dividend
- 633.00 KRW
- Payout ratio
- 66.8%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 5.00B | 440 | 66.8% |
| 2024 | KRW 2.50B | 220 | 14.8% |
| 2023 | KRW 2.50B | 220 | 193.8% |
| 2022 | KRW 2.51B | 221 | 36.5% |
| 2021 | KRW 2.52B | 221 | 64.0% |
| 2020 | KRW 2.52B | 220 | - |
| 2019 | KRW 2.52B | 220 | 99.4% |
| 2018 | KRW 2.52B | 220 | 19.1% |
| 2017 | KRW 2.52B | 220 | 30.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.01:1 on Dec 29, 2014.
Who owns Ahn-Gook Pharmaceutical Co. Ltd
- Insiders 48.22%
- Institutions 0.15%
- Public & others 51.63%
- Shares outstanding 11.4M
- Free float 5.08M
Ahn-Gook Pharmaceutical Co. Ltd company profile
- Company name
- Ahn-Gook Pharmaceutical Co. Ltd
- Ticker
- 001540.KQ
- ISIN
- KR7001540004
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 391
- Fiscal year end
- December
- Address
- 613 Siheung -daero, Seoul, South Korea
- Phone
- 82 2 3289 4226
- Website
- ahn-gook.com
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.
Ahn-Gook Pharmaceutical Co. Ltd management
3- Mr. June-Sun AuhChairman and Co-Chief Executive Officer · born 1937
- Uh JinCo-Chief Executive Officer, President and Representative Director · born 1964
- Chang-Gyun HanExecutive Officer and Director · born 1963